Similar articles

• Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.

  Turner M, Eerdekens E, Jacko M, Eerdekens M.Turner M, et al.Int Clin Psychopharmacol. 2004 Jul;19(4):241-9. doi: 10.1097/01.yic.0000133500.92025.20.Int Clin Psychopharmacol. 2004.PMID:15201572Clinical Trial.
• Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.

  Citrome L, Jaffe A, Levine J.Citrome L, et al.Schizophr Res. 2010 Jun;119(1-3):153-9. doi: 10.1016/j.schres.2010.02.1066. Epub 2010 Mar 26.Schizophr Res. 2010.PMID:20347267
• Treating Schizophrenia With 2 Long-Acting Injectable Antipsychotic Drugs: A Case Report.

  Wartelsteiner F, Hofer A.Wartelsteiner F, et al.J Clin Psychopharmacol. 2015 Aug;35(4):474-5. doi: 10.1097/JCP.0000000000000358.J Clin Psychopharmacol. 2015.PMID:26075490No abstract available.
• Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.

  Möller HJ.Möller HJ.Drugs. 2007;67(11):1541-66. doi: 10.2165/00003495-200767110-00003.Drugs. 2007.PMID:17661527Review.
• Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.

  Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ.Kirson NY, et al.J Clin Psychiatry. 2013 Jun;74(6):568-75. doi: 10.4088/JCP.12r08167. Epub 2013 Apr 19.J Clin Psychiatry. 2013.PMID:23842008Review.

Cited by

• Combination of Two Long-Acting Antipsychotics in Schizophrenia Spectrum Disorders: A Systematic Review.

  Cipolla S, Catapano P, D'Amico D, Monda R, Sallusto NP, Perris F, De Santis V, Catapano F, Luciano M, Fiorillo A.Cipolla S, et al.Brain Sci. 2024 Apr 26;14(5):433. doi: 10.3390/brainsci14050433.Brain Sci. 2024.PMID:38790412Free PMC article.Review.
• Schizophrenia treatment with a combination of two LAI antipsychotics: A case report.

  Jarosz M, Badura-Brzoza K.Jarosz M, et al.Front Psychiatry. 2022 Sep 16;13:975531. doi: 10.3389/fpsyt.2022.975531. eCollection 2022.Front Psychiatry. 2022.PMID:36186873Free PMC article.

References

Publication types

• Case Reports

MeSH terms

• Adult
• Antipsychotic Agents / administration & dosage*
• Clopenthixol / administration & dosage
• Clopenthixol / analogs & derivatives*
• Delayed-Action Preparations
• Drug Therapy, Combination / methods
• Female
• Humans
• Risperidone / administration & dosage*
• Schizophrenia / diagnosis*
• Schizophrenia / drug therapy*
• Treatment Outcome

Substances

• Antipsychotic Agents
• Delayed-Action Preparations
• clopenthixol decanoate
• Clopenthixol
• Risperidone

Related information

• PubChem Compound (MeSH Keyword)

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information